BioCardia Inc. has announced that Henry Ford Health has enrolled its first patient in the ongoing Phase 3 CardiAMP HF II clinical trial. The study is evaluating the CardiAMP cell therapy system in patients with ischemic heart failure of reduced ejection fraction (HFrEF). The trial follows previous research, including the CardiAMP-HF trial, which did not meet its primary endpoint but showed promising results in certain patient subgroups. Results from the current Phase 3 CardiAMP HF II trial have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-033949), on November 10, 2025, and is solely responsible for the information contained therein.